Jasper Therapeutics, Inc. (JSPR) intrinsic value & 10-year financials
Jasper Therapeutics, Inc. (JSPR) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.48
- Market cap
- $9.2M
- Revenue (FY2025)
- —
- Revenue growth (7-yr CAGR)
- -2.7%
- ROIC (10-yr avg)
- 919.3%
- Free cash flow (FY2025)
- —
JSPR 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$75.8M | -$3.95 | — | — | 820.4% |
| FY2024 | $8.3M | -$71.3M | -$4.89 | — | -918.5% | 960.7% |
| FY2023 | $9.0M | -$64.5M | -$6.18 | — | -765.1% | 2254.8% |
| FY2022 | — | -$37.7M | -$1.03 | — | — | 613.9% |
| FY2021 | $9.0M | -$30.6M | -$2.69 | — | -409.3% | 881.8% |
| FY2020 | — | -$590.7K | — | — | — | -16.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Jasper Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Jasper Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 6.6% ROIC.
Jasper Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Jasper Therapeutics, Inc. is modeled at -2.7% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-10.84 per share.